A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; LAG 525 (Primary) ; Ribociclib (Primary) ; Spartalizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PLATforM
- Sponsors Novartis Pharmaceuticals
- 02 Sep 2019 Planned primary completion date changed from 7 Aug 2020 to 11 Jun 2021.
- 29 Aug 2019 Planned End Date changed from 1 Jun 2021 to 31 Aug 2021.
- 02 Aug 2019 Trial has been suspended in Germany.